Avacta Group plc (AIM: AVCT), the developer of Affimer® biotherapeutics and research reagents, announces that application has been made for 5,311 new ordinary shares of 10p each (the “New Ordinary Shares”) to be admitted to trading on AIM on 16 October 2017 (“Admission”).
The New Ordinary Shares have been allotted pursuant to the purchase by Michael Albin, Non-Executive Director of the Company, of New Ordinary Shares in accordance with the terms set out in the Company’s announcement of 23 February 2016.
Following Admission, the total number of ordinary shares with voting rights in issue will be 68,403,244. Shareholders may use this figure as the denominator for the calculations by which they will determine if they are required to notify their interest in, or a change to their interest in, the Company under the Financial Conduct Authority’s Disclosure Guidance and Transparency Rules.
- Download the full RNS, including ‘Notification and public disclosure of transactions by persons discharging managerial responsibilities and persons closely associated with them’.